Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cytokines
Research
AACR: Mural debuts data for potential pipeline additions
Five months after spinning out of Alkemes, Mural Oncology has released its first data on prospective IL-18 and IL-12 therapies.
Helen Floersh
Apr 10, 2024 11:16am
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Mar 28, 2024 8:08am
Sanofi pays $40M to join preclinical push against vexing target
Jan 29, 2024 8:00am
Oncternal reports patient death in CAR-T dose-escalation study
Dec 28, 2023 10:52am
Equillium swaps subcutaneous cytokine inhibitor for oral option
Dec 21, 2023 10:58am
Xencor pulls back from Genentech cancer pact to cut costs
Nov 8, 2023 6:00am